Staphylococcal Infection Clinical Trial
Official title:
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial
IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00770341 -
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
|
Phase 3 | |
| Completed |
NCT00352612 -
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
|
Phase 4 | |
| Completed |
NCT00279864 -
The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection
|
N/A | |
| Completed |
NCT00735839 -
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
|
Phase 1 | |
| Completed |
NCT00814151 -
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
|
N/A | |
| Completed |
NCT02812446 -
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
|
N/A | |
| Completed |
NCT00846105 -
Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)
|
N/A | |
| Completed |
NCT02284555 -
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
|
Phase 4 | |
| Completed |
NCT01592214 -
Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
|
Phase 1 | |
| Completed |
NCT01827358 -
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
|
Phase 2 | |
| Completed |
NCT00730028 -
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
|
Phase 2 | |
| Completed |
NCT00729937 -
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
|
Phase 2/Phase 3 |